Latest filings (excl ownership)
S-1
IPO registration
12 Apr 24
8-K
Results of Operations and Financial Condition
12 Apr 24
424B5
Prospectus supplement for primary offering
12 Apr 24
8-K
Other Events
10 Apr 24
8-K
TRACON Pharmaceuticals Announces Reverse Stock Split
8 Apr 24
8-K
ENVASARC Trial is Fully Enrolled and Final Data are Expected in Third Quarter 2024
3 Apr 24
S-8
Registration of securities for employees
7 Mar 24
10-K
2023 FY
Annual report
5 Mar 24
8-K
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
5 Mar 24
8-K
Other Events
19 Dec 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8 Dec 23
8-K
TRACON Pharmaceuticals Announces License of Product Development Platform for $3.0 Million Upfront Payment
20 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
TRACON Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
9 Nov 23
8-K
Departure of Directors or Certain Officers
6 Oct 23
8-K
TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned
18 Sep 23
8-K
Submission of Matters to a Vote of Security Holders
7 Sep 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
TRACON Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
14 Aug 23
DEF 14A
Definitive proxy
7 Aug 23
PRE 14A
Preliminary proxy
25 Jul 23
8-K
TRACON Pharmaceuticals Announces Collection of Arbitration Award from I-Mab Biopharma
11 Jul 23
8-K
Single Agent Envafolimab ORR Exceeded Futility Rule that will be Applied at the Interim Efficacy Analysis Expected in Q3
20 Jun 23
8-K
Other Events
15 Jun 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
9 Jun 23
8-K
Unregistered Sales of Equity Securities
2 Jun 23
EFFECT
Notice of effectiveness
1 Jun 23
424B3
Prospectus supplement
31 May 23
CORRESP
Correspondence with SEC
26 May 23
UPLOAD
Letter from SEC
26 May 23
S-1
IPO registration
19 May 23
10-Q
2023 Q1
Quarterly report
10 May 23
8-K
TRACON Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
10 May 23
8-K
Termination of a Material Definitive Agreement
4 May 23
8-K
TRACON Pharmaceuticals Announces Arbitration Award in Dispute with I-Mab
25 Apr 23
8-K
Entry into a Material Definitive Agreement
20 Apr 23
8-K
Entry into a Material Definitive Agreement
6 Apr 23
8-K
Other Events
31 Mar 23
EFFECT
Notice of effectiveness
27 Mar 23
CORRESP
Correspondence with SEC
22 Mar 23
Latest ownership filings
SC 13G/A
Ikarian Capital, LLC
5 Apr 24
SC 13G/A
aaronson wayne
19 Mar 24
4
Scott B. Brown
13 Mar 24
4
CHARLES THEUER
13 Mar 24
SC 13G/A
Lincoln Park Capital Fund, LLC
14 Feb 24
SC 13D/A
Opaleye Management Inc.
9 Feb 24
4
Change in insider ownership
14 Nov 23
SC 13G
Lincoln Park Capital Fund, LLC
2 Jun 23
4
CHARLES THEUER
28 Apr 23
4
Lisa Johnson-Pratt
21 Apr 23
4
Carol C. Lam
21 Apr 23
4
SAUNDRA L PELLETIER
21 Apr 23
4
MARTIN A MATTINGLY
21 Apr 23
4
STEPHEN T WORLAND
21 Apr 23
4
WILLIAM R LARUE
21 Apr 23
4
J Rainer Twiford
21 Apr 23
4
Change in insider ownership
13 Mar 23
4
CHARLES THEUER
2 Mar 23
SC 13G/A
Ikarian Capital, LLC
14 Feb 23
SC 13G/A
aaronson wayne
10 Feb 23
4
Bonne J. Adams
9 Feb 23
3
Bonne J. Adams
9 Feb 23
4
Scott B. Brown
3 Feb 23
4
CHARLES THEUER
3 Feb 23
4
CHARLES THEUER
19 Jan 23
4
WILLIAM R LARUE
19 Jan 23
4
Scott B. Brown
3 Jan 23
4
Change in insider ownership
16 Dec 22
4
CHARLES THEUER
15 Dec 22
4
Change in insider ownership
8 Dec 22
4
CHARLES THEUER
22 Nov 22
4
CHARLES THEUER
4 Nov 22
4
CHARLES THEUER
3 Nov 22
4
Change in insider ownership
19 Oct 22
4
CHARLES THEUER
11 Oct 22
4
CHARLES THEUER
5 Oct 22
4
Change in insider ownership
3 Oct 22
4
Change in insider ownership
28 Sep 22
4
CHARLES THEUER
26 Sep 22
4
Change in insider ownership
22 Sep 22